OKMO 6/5

## Serum Transferrin Receptor as a Marker of Erythropoiesis in β Thalassemia Major

## Thesis Submitted for Partial Fulfillment of Master Degree in Pediatrics

BY

**Amany Mohamed Hassan** 

M.B.B.Ch., Faculty of Medicine, Ain Shams University

Supervised By 65819

Prof. Dr. Galila Mohamed Mokhtar

Professor of Pediatrics
Faculty of Medicine - Ain Shams University

Dr. Ashraf Abdel Baky Salama

Lecturer of Pediatrics
Faculty of Medicine - Ain Shams University

Dr. Hanaa Mohamed Afify

Assistant Professor of Clinical Pathology
Faculty of Medicine - Ain Shams University

Faculty of Medicine Ain Shams University

\*\*\* 1999 \*\*\*

1 16



## Acknowledgment

Ļ

I wish to express my deep appreciation and gratitude to **Prof. Dr. Galila Mohamed Mokhtar**, Professor of Pediatrics, Faculty of Medicine, Ain Shams University, for giving me the privilege of working under her supervision and helpful guidance. Her advice was always stimulating and essential to complete this work.

I also feel greatly indebted to **Dr. Ashraf Abdel Baki Salama**, Lecturer of Pediatrics, Faculty of Medicine, Ain Shams University, for his sincere help, meticulous guidance and encouragement throughout this work.

I am also sincerely grateful to **Dr. Hanaa Mohamed Afify**, Assistant Professor of Clinical Pathology, Faculty of Medicine, Ain Shams University, for her precious time and effort she gave me.

I also wish to express my deep thanks to all my patients and their parents for their kindness without which this piece of work would have never been completed.

Amany Mohamed

ļ

## **Table of Contents**

		PAGE
List of Tables	S	
List of Figure	es	
List of Abbre	viations	
Introduction	l	t
Aim of the V	Vork	2
Review of Literature		3 – 45
Chapter (I):	Beta Thalassemia Major	
	- Definition	3
	- Pathophysiology of β-Thalassemia Major	4
	- Molecular Pathology of β-Thalassemia Major	5
	- Diagnosis of β-Thalassemia Major	6
	- Treatment of β-Thalassemia Major	9
	Transfusion Therapy	9
	Chelation Therapy	13
	<ul> <li>Splenectomy</li> </ul>	14
	Bone Marrow Transplantation	16
	Supportive care	17

Chapter (H):	Iron Metabolism in β-Thalassemia	
	1. Normal Iron Metabolism	
	Iron Requirement	20
	• Iron Absorption	20
	<ul> <li>Transport and Storage of Body Iron</li> </ul>	24
	Iron Excretion	25
	<ul> <li>Proteins of Iron Transport and Storage</li> </ul>	25
	2. Iron in Thalassemia Major	
	<ul> <li>Causes of Iron Overload in Thalassemia</li> </ul>	28
	<ul> <li>Mechanism of Iron Toxicity</li> </ul>	29
	<ul> <li>Effect of Iron Overload</li> </ul>	30
	<ul> <li>Evaluation of Iron Overload</li> </ul>	31
	<ul> <li>Management of Iron Overload (Chelation Therapy)</li> </ul>	34
Chapter (III):	Transferrin Receptors	
	1. Cellular Transferrin Receptors	
	• Structure	37
	• Function	37
	<ul> <li>Factors Regulating the Receptors</li> </ul>	37
	Clinical Relevance of Cellular TFR	38
	Erythroid Marrow Activity from Ferrokinetic Measurements to Circulating TFR	40
	3. Circulating Transferrin Receptor	41
	• Structure	41
	<ul> <li>Level of Circulating TFR</li> </ul>	42
	Clinical Relevance of Circulating TFR	.13

	Subjects and Methods	46
	Subjects	46
	Methods	48
i	The Results	
	Raw Data	52
	Results	62
	Discussion	94
	Conclusion	103
	Summary	104
	Recommendations	106
	References	107
ļ.	Arabic Summary	

#### **List of Tables**

No.	Table	Page
Table (1):	The main types of beta thalassemia.	5
Table (2):	Clinical data of non-splenectomized group.	53
Table (3):	Laboratory data of non-splenectomized group.	55
Table (4):	Clinical data of splenectomized group.	57
Table (5):	Laboratory data of splenectomized group.	58
Table (6):	Clinical and laboratory data of control group.	59
Table (7):	Descriptive statistics of the studied group.	61
Table (8):	Comparison between control group and all studied patients as regard weight and height centiles.	62
Table (9):	Comparison between splenectomized and non- splenectomized group as regard age, duration of illness, weight and height centiles, frequency of blood transfusion per year.	63
Table (10):	Comparison between splenectomized and non- splenectomized patients above 6 years old as regard weight and height centiles and frequency of blood transfusion.	64
Table (11):	Comparison between packed washed group and packed unwashed group as regard age, weight, height centiles, duration of transfusion and frequency of transfusion per year.	65
Table (12):	Comparison between control group and all studied patients as regard complete blood count parameters.	66

No.	No. Table	
Table (13):	Comparison between splenectomized and non-splenectomized group as regard complete blood count parameters.	67
Table (14):	Comparison between splenectomized and non-splenectomized above 6 years old as regard CBC parameters.	68
Table (15):	Comparison between packed washed and packed unwashed group as regard complete blood count parameters.	69
Table (16):	Comparison between splenectomized and non-splenectomized patients above 6 years old as regard serum iron, TIBC, ferritin and TFR.	80

### **List of Figures**

No.	Figure	Page
Figure (1):	Pathophysiology of beta thalassemia major.	4
Figure (2):	Diagnosis of beta thalassemia major.	
Figure (3):	Intestinal mucosal regulation of iron absorption.	
Figure (4):	Iron transport and metabolism.	
Figure (5):	Pretransfusion hemoglobin in the studied samples in comparison to the control.	
Figure (6):	Soluble transferrin receptor in the studied sample in comparison to the control.	73
Figure (7):	Serum iron in the studied samples in comparison to the control.	75
Figure (8):	Serum total iron binding capacity in the studied samples in comparison to the control.	77
Figure (9):	Scrum ferritin in the studied patients in comparison to the control.	79
Figure (10):	Comparison between patients with STFR more than 5 double the normal level and those with STFR less than 5 double the normal level as regard frequency of transfusion, pretransfusion hemoglobin, s. iron and s. TIBC.	
Figure (11): Comparison between patients with STFR more than 5 double the normal level and those with STFR less than 2 double the normal level and the control group as regard frequency of blood transfusion per year, pretransfusion hemoglobin, s. iron, and s. TIBC.		84

No.	Figure	Page
Figure (12):	Correlation between serum transferrin receptor and pretransfusion hemoglobin in all studied patients.	85
Figure (13):	Correlation between serum transferrin receptor and average of pretransfusion hemoglobin in all studied patients.	87
Figure (14);	Correlation between serum transferrin receptor and hemoglobin A in all studied patients.	88
Figure (15):	Correlation between serum transferrin receptor and hemoglobin F in all studied patients.	89
Figure (16):	Correlation between soluble transferrin receptor and reticulocytic count in all studied patients.	90
Figure (17):	Correlation between serum transferrin receptor and serum iron in all studied patients.	91
Figure (18):	Correlation between soluble transferrin receptor and total iron binding capacity (TIBC) in all studied patients.	92
Figure (19):	Correlation between pretransfusion hemoglobin and serum iron in all studied patients.	93

#### **List of Abbreviations**

CBC : Complete blood count

ETU : Erythron transferrin uptake

Fe : Iron

FL : Femoto-liter = 1/10<sup>15</sup> liter

γ-GT Gamma glutamyl transpeptidase

Hb : Hemoglobin

MCV : Mean corpuscular volume

MCH : Mean corpuscular hemoglobin

MCHC Mean corpuscular hemoglobin concentration

RC : Reticulocytic count

RBC : Red blood cells

pg :  $Picogram = 1 / 10^{12} gm$ 

TFR Transferrin receptor

TIBC : Total iron binding capacity

TLC : Total leukocytic count

U/mL : Unit per milliliter

# INTRODUCTION